Dr. Mason Freeman M.D. serves as Independent Director of the Company. Dr. Freeman is a Venture Partner at 5AM Venture Management, LLC, a life science focused investment firm, which he joined initially as scientific advisor in 2007. He is Chief of the Lipid Metabolism Unit and director of the Translational Research Center at Massachusetts General Hospital (MGH), as well as a Professor of Medicine at Harvard Medical School. Prior to this, Dr. Freeman was head of the Novartis translational medicine program for cardiovascular & metabolic diseases as well as global head of biomarker development. Dr. Freeman currently serves on the scientific advisory boards of Homology Medicines, Inc. and Mitobridge, Inc., a biotechnology company that was acquired by Astellas Pharma Inc. in January 2018. Dr. Freeman previously served as clinical advisor to Relypsa, Inc., a biopharmaceutical company focused on polymer therapeutics and was a director of Crinetics Pharmaceuticals and Envoy Therapeutics, Inc., a biopharmaceutical company that was acquired by Takeda. Dr. Freeman holds a B.A. from Harvard College and a M.D. from the University of California, San Francisco. Freeman is qualified to serve on our board of directors because of his industry experience, medical and clinical knowledge, and his experience of serving on the board of directors and scientific advisory board for several biopharmaceutical companies.
As the Independent Director of scPharmaceuticals Inc, the total compensation of Mason Freeman at scPharmaceuticals Inc is $46,006. There are 10 executives at scPharmaceuticals Inc getting paid more, with John Tucker having the highest compensation of $1,238,320.
Mason Freeman is 69, he's been the Independent Director of scPharmaceuticals Inc since 2018. There are 3 older and 8 younger executives at scPharmaceuticals Inc. The oldest executive at scPharmaceuticals Inc is Leonard Schaeffer, 74, who is the Independent Director.
Mason's mailing address filed with the SEC is 2400 District Ave #310, Burlington, MA 01803, USA.
Over the last 7 years, insiders at scPharmaceuticals Inc have traded over $5,999,254 worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth $61,370,807 . The most active insiders traders include Capital Management, L.P.Ra ..., Jonathan Silverstein, and Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of $1,808,281. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth $29,275.
scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
scPharmaceuticals Inc executives and other stock owners filed with the SEC include: